Cargando…

Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease

Lafora disease (LD) is a fatal progressive epilepsy essentially caused by loss‐of‐function mutations in the glycogen phosphatase laforin or the ubiquitin E3 ligase malin. Glycogen in LD is hyperphosphorylated and poorly hydrosoluble. It precipitates and accumulates into neurotoxic Lafora bodies (LBs...

Descripción completa

Detalles Bibliográficos
Autores principales: Nitschke, Felix, Sullivan, Mitchell A, Wang, Peixiang, Zhao, Xiaochu, Chown, Erin E, Perri, Ami M, Israelian, Lori, Juana‐López, Lucia, Bovolenta, Paola, Rodríguez de Córdoba, Santiago, Steup, Martin, Minassian, Berge A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494504/
https://www.ncbi.nlm.nih.gov/pubmed/28536304
http://dx.doi.org/10.15252/emmm.201707608
_version_ 1783247687235141632
author Nitschke, Felix
Sullivan, Mitchell A
Wang, Peixiang
Zhao, Xiaochu
Chown, Erin E
Perri, Ami M
Israelian, Lori
Juana‐López, Lucia
Bovolenta, Paola
Rodríguez de Córdoba, Santiago
Steup, Martin
Minassian, Berge A
author_facet Nitschke, Felix
Sullivan, Mitchell A
Wang, Peixiang
Zhao, Xiaochu
Chown, Erin E
Perri, Ami M
Israelian, Lori
Juana‐López, Lucia
Bovolenta, Paola
Rodríguez de Córdoba, Santiago
Steup, Martin
Minassian, Berge A
author_sort Nitschke, Felix
collection PubMed
description Lafora disease (LD) is a fatal progressive epilepsy essentially caused by loss‐of‐function mutations in the glycogen phosphatase laforin or the ubiquitin E3 ligase malin. Glycogen in LD is hyperphosphorylated and poorly hydrosoluble. It precipitates and accumulates into neurotoxic Lafora bodies (LBs). The leading LD hypothesis that hyperphosphorylation causes the insolubility was recently challenged by the observation that phosphatase‐inactive laforin rescues the laforin‐deficient LD mouse model, apparently through correction of a general autophagy impairment. We were for the first time able to quantify brain glycogen phosphate. We also measured glycogen content and chain lengths, LBs, and autophagy markers in several laforin‐ or malin‐deficient mouse lines expressing phosphatase‐inactive laforin. We find that: (i) in laforin‐deficient mice, phosphatase‐inactive laforin corrects glycogen chain lengths, and not hyperphosphorylation, which leads to correction of glycogen amounts and prevention of LBs; (ii) in malin‐deficient mice, phosphatase‐inactive laforin confers no correction; (iii) general impairment of autophagy is not necessary in LD. We conclude that laforin's principle function is to control glycogen chain lengths, in a malin‐dependent fashion, and that loss of this control underlies LD.
format Online
Article
Text
id pubmed-5494504
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54945042017-07-05 Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease Nitschke, Felix Sullivan, Mitchell A Wang, Peixiang Zhao, Xiaochu Chown, Erin E Perri, Ami M Israelian, Lori Juana‐López, Lucia Bovolenta, Paola Rodríguez de Córdoba, Santiago Steup, Martin Minassian, Berge A EMBO Mol Med Research Articles Lafora disease (LD) is a fatal progressive epilepsy essentially caused by loss‐of‐function mutations in the glycogen phosphatase laforin or the ubiquitin E3 ligase malin. Glycogen in LD is hyperphosphorylated and poorly hydrosoluble. It precipitates and accumulates into neurotoxic Lafora bodies (LBs). The leading LD hypothesis that hyperphosphorylation causes the insolubility was recently challenged by the observation that phosphatase‐inactive laforin rescues the laforin‐deficient LD mouse model, apparently through correction of a general autophagy impairment. We were for the first time able to quantify brain glycogen phosphate. We also measured glycogen content and chain lengths, LBs, and autophagy markers in several laforin‐ or malin‐deficient mouse lines expressing phosphatase‐inactive laforin. We find that: (i) in laforin‐deficient mice, phosphatase‐inactive laforin corrects glycogen chain lengths, and not hyperphosphorylation, which leads to correction of glycogen amounts and prevention of LBs; (ii) in malin‐deficient mice, phosphatase‐inactive laforin confers no correction; (iii) general impairment of autophagy is not necessary in LD. We conclude that laforin's principle function is to control glycogen chain lengths, in a malin‐dependent fashion, and that loss of this control underlies LD. John Wiley and Sons Inc. 2017-05-23 2017-07 /pmc/articles/PMC5494504/ /pubmed/28536304 http://dx.doi.org/10.15252/emmm.201707608 Text en © 2017 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the Creative Commons Attribution 4.0 (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Nitschke, Felix
Sullivan, Mitchell A
Wang, Peixiang
Zhao, Xiaochu
Chown, Erin E
Perri, Ami M
Israelian, Lori
Juana‐López, Lucia
Bovolenta, Paola
Rodríguez de Córdoba, Santiago
Steup, Martin
Minassian, Berge A
Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease
title Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease
title_full Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease
title_fullStr Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease
title_full_unstemmed Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease
title_short Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease
title_sort abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in lafora disease
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494504/
https://www.ncbi.nlm.nih.gov/pubmed/28536304
http://dx.doi.org/10.15252/emmm.201707608
work_keys_str_mv AT nitschkefelix abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT sullivanmitchella abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT wangpeixiang abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT zhaoxiaochu abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT chownerine abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT perriamim abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT israelianlori abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT juanalopezlucia abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT bovolentapaola abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT rodriguezdecordobasantiago abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT steupmartin abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease
AT minassianbergea abnormalglycogenchainlengthpatternnothyperphosphorylationiscriticalinlaforadisease